FDA Approves Shingrix Vaccine For Use In Adults 18 Years And Older With Increased Risk Of Immunodeficiency Or Immunosuppression, Company Announces
July 27, 2021
HCPlive (7/26, Butera) reports in a July 26 news release (7/26), GlaxoSmithKline announced the FDA’s approval of “the non-live, recombinant sub-unit adjuvanted vaccine Shingrix for the prevention of shingles in adults aged 18 years and older with increase...